P=N/A, N=150, Recruiting, Hospices Civils de Lyon | Not yet recruiting --> Recruiting | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Dec 2026 --> Aug 2027

P1, N=18, Recruiting, Vertex Pharmaceuticals Incorporated | Not yet recruiting --> Recruiting

P4, N=32, Completed, Emory University | Recruiting --> Completed

There is a gap in healthcare for pwCF, especially for those who do not routinely interact with a PCP. CF clinicians may not be up to date on primary care management and PCPs may not be comfortable with treating patients with a high acuity chronic condition. PCPs should be better integrated into the CF care team to ensure pwCF are receiving comprehensive care.

P=N/A, N=150, Recruiting, Meyer Children's Hospital IRCCS

P1, N=18, Not yet recruiting, Vertex Pharmaceuticals Incorporated

Flow cytometry was used to assess apoptosis, DNA damage and cell proliferation following treatment with either 15 µM ivacaftor or 30 µM carboplatin at 24, 48 and 72 h. ROR1 signalling associated oncogenic pathways including the BMI-1 and the PI3K/AKT pathways were modulated following ivacaftor treatment. In summary, ivacaftor demonstrated significant anti-tumour potential in preclinical HGSOC models, supporting its further investigation as a repurposed therapy for ovarian cancer.

P=N/A, N=130, Not yet recruiting, University Hospital, Lille

P=N/A, N=150, Not yet recruiting, Hospices Civils de Lyon

P=N/A, N=270, Recruiting, Hospices Civils de Lyon | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Sep 2025 --> Sep 2026

P3, N=70, Completed, Vertex Pharmaceuticals Incorporated | Active, not recruiting --> Completed

P3, N=50, Active, not recruiting, Vertex Pharmaceuticals Incorporated | Enrolling by invitation --> Active, not recruiting